EAM Investors’s Sarepta Therapeutics SRPT Stock Holding History

EAM Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,491	Closed	-$1.1M	–	358
2022 Q4	$1.1M	Sell	8,491 -4,198	-33%	-$486K	0.23%	211
2022 Q3	$1.4M	Buy	+12,689	New	+$1.28M	0.31%	142
2019 Q1	–	Sell	-8,722	Closed	-$952K	–	314
2018 Q4	$952K	Sell	8,722 -6,044	-41%	-$756K	0.26%	174
2018 Q3	$2.38M	Sell	14,766 -10,926	-43%	-$1.49M	0.35%	136
2018 Q2	$3.4M	Sell	25,692 -14,288	-36%	-$1.35M	0.54%	55
2018 Q1	$2.96M	Sell	39,980 -9,940	-20%	-$663K	0.49%	92
2017 Q4	$2.78M	Sell	49,920 -11,235	-18%	-$595K	0.5%	59
2017 Q3	$2.77M	Buy	+61,155	New	+$2.44M	0.37%	83
2016 Q4	–	Sell	-57,186	Closed	-$3.51M	–	360
2016 Q3	$3.51M	Buy	+57,186	New	+$1.73M	0.47%	53

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's SRPT Position: Q1 2023 in Review

EAM Investors sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 8,491 shares — an estimated $1.1M sold.

EAM Investors first reported a position in SRPT in Q3 2016 and held it in 9 quarters. The position peaked at $3.51M in Q3 2016. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

EAM Investors reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 8,491 Sarepta Therapeutics shares in Q1 2023, an estimated $1.1M.
EAM Investors first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 9 quarters.
EAM Investors's Sarepta Therapeutics position peaked at $3.51M in Q3 2016.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.